Saltar al contenido
Merck

Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells.

Genes & development (2006-06-02)
Barna D Fodor, Stefan Kubicek, Masato Yonezawa, Roderick J O'Sullivan, Roopsha Sengupta, Laura Perez-Burgos, Susanne Opravil, Karl Mechtler, Gunnar Schotta, Thomas Jenuwein
RESUMEN

Histone lysine trimethyl states represent some of the most robust epigenetic modifications in eukaryotic chromatin. Using a candidate approach, we identified the subgroup of murine Jmjd2 proteins to antagonize H3K9me3 at pericentric heterochromatin. H3K27me3 and H4K20me3 marks are not impaired in inducible Jmjd2b-GFP cell lines, but Jmjd2b also reduces H3K36 methylation. Since recombinant Jmjd2b appears as a very poor enzyme, we applied metabolic labeling with heavy methyl groups to demonstrate Jmjd2b-mediated removal of chromosomal H3K9me3 as an active process that occurs well before replication of chromatin. These data reveal that certain members of the jmjC class of hydroxylases can work in a pathway that actively antagonizes a histone lysine trimethyl state.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
JMJD2b active human, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE)
Sigma-Aldrich
KDM4DL human, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE)